| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Geoffrey Clapp | CXO | 2026-11-11 | 774 | $36.41 | $28.18kSell |
| Peter Anevski | CEO | 2026-11-10 | 18,059 | $36.29 | $655.27kSell |
| David J. Schlanger | Chair | 2026-11-10 | 35,392 | $35.36 | $1.25MSell |
| Peter Anevski | CEO | 2026-11-10 | 33,437 | $35.61 | $1.19MSell |
| David J. Schlanger | Chair | 2026-11-10 | 35,392 | $0.91 | $32.21kBuy |
| Peter Anevski | CEO | 2026-11-10 | 185,134 | $0.91 | $168.47kBuy |
| Peter Anevski | CEO | 2026-11-10 | 120,213 | $35.61 | $4.28MSell |
| Peter Anevski | CEO | 2026-11-10 | 64,921 | $36.29 | $2.36MSell |
| Peter Anevski | CEO | 2026-11-09 | 126,204 | $35.73 | $4.51MSell |
| David J. Schlanger | Chair | 2026-11-09 | 161,208 | $35.73 | $5.76MSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Tpg Group Holdings Sbs Advisors Inc | 13.58% | 10,000,000 | $367.10M | Insider |
| Kleiner Perkins Caufield Byers XIII LLC | 10.10% | 7,435,609 | $272.96M | Insider |
| Tpg GP A LLC | 8.62% | 6,350,000 | $233.11M | Insider |
| Glaxosmithkline PLC | 8.47% | 6,238,244 | $229.01M | Insider |
| Norman Payson | 2.53% | 1,864,265 | $68.44M | Insider |
| Karin Ajmani | 1.53% | 1,128,560 | $41.43M | Insider |
| Peter Anevski | 1.18% | 870,475 | $31.96M | Insider |
| Beth C. Seidenberg | 0.37% | 271,322 | $9.96M | Insider |
| Michael E. Sturmer | 0.35% | 255,205 | $9.37M | Insider |
| David J. Schlanger | 0.32% | 238,462 | $8.75M | Insider |